Skip to content
Palanor is in early release, with our founding customers.Become a founding customer →
The Real Rate Index45.30.00Palanor: Inflation Pulse50.7+0.09Palanor: Geopolitical Stress60.0-2.16Palanor: Liquidity57.9-0.79Palanor: Capital Tightness47.5+0.91Palanor: Industrial Pulse70.10.00Palanor: AI Margin Compression53.4+0.29Palanor: Consumer Confidence48.6+0.50Palanor: US Dollar Strength46.50.00Palanor: Labor Heat63.2-0.01Palanor: Recession Vocabulary28.1+0.54Palanor: Uncertainty Index53.4+1.24Palanor: US Jobs Health40.30.00Palanor: Energy Transition37.0-0.52Palanor: Reshoring Sentiment22.8+0.54Palanor: AI Substitution28.4-0.24The Social Fabric Index45.70.00Palanor: Geopolitical Anxiety19.4-0.45Palanor: Quit Pressure37.6+0.42The Mania Index88.00.00The Palanor Index57.1-0.51Cost Disease Spread33.20.00Palanor: US vs China49.5-0.17Rise of Socialism Index40.8-0.26The Bubble Memory79.90.00Palanor: Steward Confidence50.8+0.13The Long Watch90.30.00The Reshoring Index55.2+0.00The Capital Return Index81.0-0.75The Discourse Index72.4+1.83The Hesitation Index30.8-6.58Palanor AI Inference Cost Index71.2-0.03The AI Capex Race Index78.4+1.36The Boardroom Index82.5-0.00The Layoff Cycle Index32.8-2.51Capital Deployment Posture Index62.3+1.26The Consumer Health Index41.7-2.96Labor Hours Composite44.40.00The Dollar Erosion Index66.6+0.14Palanor: Risk Appetite36.2+0.83
PalanorPalanor

Company Dossier · Health Care

Moderna

MRNANasdaqBiotechnologyWILMINGTON, US-DE, USLarge capWebsite ↗
  • S&P 500
  • Russell 1000

What Moderna is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.

Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →

The latest read

Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.

  • Revenue over the four quarters to June 30, 2026: $2.23 billion, down 28% from a year earlier.SEC EDGAR filings (XBRL)
  • Free cash flow (operating cash flow minus capital expenditure) over the four quarters to June 30, 2026: −$1.24 billion.SEC EDGAR filings (XBRL)
  • Capital expenditure over the four quarters to June 30, 2026: $0.17 billion, down 78% from a year earlier.SEC EDGAR filings (XBRL)
  • Latest earnings call or results release (July 31, 2026): sentiment 0.30 on a −1 to +1 scale (mixed), confidence 0.60 of 1.Palanor Discourse
  • Guidance in the last 90 days: 1 outlook figure raised, 2 lowered, 1 held.Guidance Ledger (8-K results releases)
  • Latest annual report (filed February 20, 2026): 4 risk factors added, 1 removed.Risk Factor Changes (10-K Item 1A)
  • Insiders were net sellers in Q3 2026: $49.2 million on the open market.SEC Form 4
  • 788 institutional managers reported a position at June 30, 2026 (+61 on the quarter before).SEC Form 13F
  • H-1B filings certified in Q2 2026: 46 (65 a year earlier).U.S. Department of Labor (OFLC)
  • Headlines in the last 30 days: 17, of which 0 read positive and 1 negative.Palanor headline tone

Company Posture

How Company Posture is measured →

What Moderna is doing, on three axes, from its filings and its own words, as of 2026-10-22. A description, not a rating: Company Posture never says whether to buy.

Retrenching · Mixed

Expanding ↔ Retrenching

Retrenching

RetrenchingExpanding

Confident ↔ Hedging

Mixed

HedgingConfident

Pressure

Components only: Not yet shown as a score: in the back-test it did not add to a naive reader's forecast of impairment, debt acceleration or bankruptcy filings (8-K 2.06, 2.04, 1.03) (not enough events (17 in half 1; needs 20)).

Credit

How these are built →

Moderna's borrowing from its SEC filings: the bonds it priced and the debt on its latest balance sheet. A description, not a rating.

Debt on the balance sheet

$0.6B

  • Due within a year $0.0B
  • Longer term $0.6B
  • Default point $0.3B (short + ½ long)

Finance leases included · Jun 30, 2026 filing

Bonds priced, last 12 months

None

U.S. dollar tranches with a term sheet on EDGAR. Deals sold under Rule 144A file none and are not counted.

Charts

Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.

Cash flow

Business

Moderna: free cash flow, trailing twelve months

Operating cash flow minus capital expenditure, $ billions, from SEC filings

−$1.2BData to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Moderna: operating cash flow and capital expenditure

Trailing twelve months, $ billions, from SEC filings

Data to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Moderna: revenue, trailing twelve months

$ billions, from SEC filings

$2.2BData to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR

Capital returned and raised

Business

Moderna: share buybacks by fiscal year

Cash paid to repurchase common stock, $ billions, from the 10-K

$0.0BData to Dec 2025
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Moderna: debt due within a year and cash

At each balance-sheet date, $ billions, from SEC filings

Data to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR

What the company says

Business

Moderna: guidance raised minus lowered

Guidance Ledger statements by quarter

−1.0Data 23 days ago
ImageDataGuidance Ledger by Palanor · source: SEC EDGAR
Business

Moderna: earnings call sentiment

Palanor Discourse score per call, −1 to +1

0.30Data to Jul 2026
ImageDataPalanor calculation
Business

Moderna: earnings call confidence

Palanor Discourse score per call, 0 to 1

0.60Data to Jul 2026
ImageDataPalanor calculation
Business

Moderna: risk factors added per annual report

New Item 1A risk factors in each 10-K

4.0Data to Feb 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR

Hiring and ownership

Business

Moderna: H-1B filings certified

Labor Condition Applications by quarter received

46.0Data to Jun 2026
ImageDataU.S. Department of Labor, Office of Foreign Labor Certification disclosure data, dol.gov
Business

Moderna: insider net buying

Open-market purchases minus sales by officers and directors, $ millions, by quarter

−$49.2MData 23 days ago
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Moderna: institutional holders

Managers reporting a position on Form 13F, by quarter

788.0Data to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR

News

Business

Moderna: headline tone

Net share of positive headlines, trailing 28 days, −1 to +1

−0.06Data 6 days ago
ImagePalanor calculation from news headlines (tone words only)

In the news

Headlines that name Moderna, with the publisher and a link. The tone is read from each headline’s own words, never from a summary of the article.

30 days
17 headlines
0% positive · 6% negative
90 days
30 headlines
20% positive · 3% negative

Filings and records

The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.

  1. Oct 20, 2026Lobbying
    Lobbying report (AVENUE SOLUTIONS)third_quarter 2026 · $0.1 million
  2. Oct 20, 2026Lobbying
    Lobbying report (HEALTH POLICY SOURCE, INC.)third_quarter 2026 · $0.1 million
  3. Oct 20, 2026Lobbying
    Lobbying report (STANTON PARK GROUP)third_quarter 2026 · $0.1 million
  4. Oct 16, 2026Lobbying
    Lobbying report (MODERNA, INC.)third_quarter 2026 · $0.1 million
  5. Oct 7, 2026Lobbying
    Lobbying report (HOLLAND & KNIGHT LLP)third_quarter 2026 · $0.0 million
  6. Oct 6, 2026Patent
    Patent granted: MUTANT INFLUENZA B/VICTORIA LINEAGE VIRUS HEMAGGLUTININ PROTEINSUS 12752001
  7. Sep 30, 20268-K
    Director or officer changeItem 5.02
  8. Sep 22, 2026Patent
    Patent granted: NOVEL HEADGROUP LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTSUS 12740943
  9. Sep 22, 2026Patent
    Patent granted: VARIANT STRAIN-BASED CORONAVIRUS VACCINESUS 12741019
  10. Sep 1, 20268-K
    Material agreement signedItem 1.01
  11. Jul 28, 2026Patent
    Patent granted: STABILIZED FORMULATIONSUS 12691177
  12. Jul 21, 2026Patent
    Patent granted: POLYNUCLEOTIDES ENCODING PROPIONYL-COA CARBOXYLASE ALPHA AND BETA SUBUNITS FOR THE TREATMENT OF PROPIONIC ACIDEMIAUS 12685785
  13. Jul 20, 2026Lobbying
    Lobbying report (STANTON PARK GROUP)second_quarter 2026 · $0.1 million
  14. Jul 20, 2026Lobbying
    Lobbying report (AVENUE SOLUTIONS)second_quarter 2026 · $0.1 million
  15. Jul 16, 2026Lobbying
    Lobbying report (BROWNSTEIN HYATT FARBER SCHRECK, LLP)second_quarter 2026 · $0.1 million
  16. Jul 8, 20268-K
    Director or officer changeItem 5.02
  17. May 11, 20268-K
    Shareholder vote resultsItem 5.07
  18. Mar 5, 20268-K
    Material agreement signedItem 1.01
  19. Feb 20, 202610-K
    Annual report (10-K)4 risk factors added, 1 removed
  20. Nov 24, 20258-K
    Material agreement signedItem 1.01
  21. Nov 13, 20258-K
    Shareholder vote resultsItem 5.07
  22. May 5, 20258-K
    Shareholder vote resultsItem 5.07
  23. Feb 21, 202510-K
    Annual report (10-K)2 risk factors added, 2 removed
  24. Feb 23, 202410-K
    Annual report (10-K)3 risk factors added, 3 removed

Peers

Companies in the same industry in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.

CompanyRevenueFree cash flowThrough
Exelixis EXEL$2.4B$1.2BJul 3, 2026
Halozyme HALO$1.7B$0.8BJun 30, 2026
United Therapeutics UTHR$3.1B$1.1BJun 30, 2026
Neurocrine Biosciences NBIX$3.4B$0.6BJun 30, 2026
Insmed INSM$1.1B−$0.8BJun 30, 2026
Caris Life Sciences CAI$1.0B$0.1BJun 30, 2026
Incyte INCY$5.4B—Mar 31, 2026
Repligen RGEN$0.8B$0.1BJun 30, 2026

Identity

SEC CIK
1682852
LEI
549300EI6OKH5K5Q2G38
Wikidata
Q17081612
SAM UEI
LCY4PQS5SV44
SAM UEI
YHJKNMMBLKQ3

Built from SEC EDGAR filings (public domain), the Guidance and KPI Ledgers, Palanor Discourse, U.S. Department of Labor filings, USPTO, USAspending and Senate lobbying records, and rights-checked news headlines. Updated nightly; this page was built Oct 22, 2026. How the Dossier is built

S&P 500, S&P 100, S&P MidCap 400 and Dow Jones Industrial Average are trademarks of S&P Dow Jones Indices LLC or its affiliates; Nasdaq-100 is a trademark of Nasdaq, Inc.; Russell 1000 is a trademark of FTSE Russell. Membership is shown for identification only. Palanor is not affiliated with or endorsed by the index owners.

Cookies

We only use essential cookies to keep you signed in and remember your theme. No analytics, no tracking, no ads. See the Privacy Policy for the full read.